Intracoronary Radiotherapy for Restenosis

Publisher Website
Google Scholar
Abstract
On November 3, 2000, the Food and Drug Administration (FDA) granted approval for two devices that deliver intracoronary radiotherapy for in-stent restenosis. Given this approval, it is possible that there will be widespread dissemination of this technique before its safety and efficacy have been established. Before interventional cardiologists wholeheartedly embrace this new technology, it should receive a thorough and unbiased assessment by impartial parties.1 More than 500,000 percutaneous coronary revascularization procedures are performed each year in North America.2 Restenosis occurs in 30 to 40 percent of patients within six months after balloon angioplasty and in 20 to 30 percent of . . .